Chimeric Antigen Receptors for T-Cell Malignancies.
T cell malignancy
T-cells
chimeric antigen receptors (CARs)
immunotherapy
non-Hodgkin lymphoma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
12
2018
accepted:
12
02
2019
entrez:
21
3
2019
pubmed:
21
3
2019
medline:
21
3
2019
Statut:
epublish
Résumé
Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells with CARs targeted to these shared antigens can therefore promote over-activation or fratricide of CAR T cells, reducing their therapeutic potency. If fratricide is resolved, clinical CAR T cell activity may eliminate normal T-cell subsets and cause temporary immunosuppression. In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.
Identifiants
pubmed: 30891427
doi: 10.3389/fonc.2019.00126
pmc: PMC6411696
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
126Subventions
Organisme : NCI NIH HHS
ID : P01 CA094237
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA126752
Pays : United States
Références
Mol Cell Biol. 1999 Apr;19(4):2903-12
pubmed: 10082557
Am J Clin Pathol. 1999 Apr;111(4):467-76
pubmed: 10191766
J Immunol Methods. 2000 Sep 21;243(1-2):59-75
pubmed: 10986407
Blood. 2000 Dec 15;96(13):4046-54
pubmed: 11110672
Thromb Res. 2001 Feb 15;101(4):279-89
pubmed: 11248289
Am J Clin Pathol. 2001 Oct;116(4):512-26
pubmed: 11601136
Cell. 2002 Jan 25;108(2):153-64
pubmed: 11832206
Blood. 2002 Mar 1;99(5):1505-11
pubmed: 11861261
Annu Rev Immunol. 2002;20:253-300
pubmed: 11861604
Cancer Cell. 2002 Mar;1(2):133-43
pubmed: 12086872
Mod Pathol. 2002 Aug;15(8):838-44
pubmed: 12181269
Blood. 2002 Dec 15;100(13):4537-43
pubmed: 12393419
J Am Acad Dermatol. 2003 Jan;48(1):23-30
pubmed: 12522366
J Immunol. 2003 May 1;170(9):4623-9
pubmed: 12707340
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3625-34
pubmed: 14506150
J Immunol. 2004 Mar 1;172(5):2953-61
pubmed: 14978098
J Leukoc Biol. 2005 Jul;78(1):43-50
pubmed: 15817704
Leukemia. 2005 Aug;19(8):1376-83
pubmed: 15931266
Med Oncol. 2005;22(2):191-4
pubmed: 15965283
J Clin Oncol. 2006 Jun 1;24(16):2472-9
pubmed: 16636342
J Immunol. 2006 Oct 1;177(7):4488-94
pubmed: 16982885
Blood. 2007 Jun 1;109(11):4655-62
pubmed: 17311990
Nat Immunol. 2007 Jun;8(6):639-46
pubmed: 17486092
J Immunol. 2007 Jun 1;178(11):6821-7
pubmed: 17513730
J Exp Med. 2007 Aug 6;204(8):1849-61
pubmed: 17635957
J Immunol. 2007 Oct 1;179(7):4335-44
pubmed: 17878328
J Clin Oncol. 2007 Dec 1;25(34):5458-64
pubmed: 17968021
Pathol Int. 2008 Feb;58(2):89-97
pubmed: 18199158
Blood. 1991 Apr 1;77(7):1546-54
pubmed: 1826223
Blood. 1991 Sep 1;78(5):1173-82
pubmed: 1878584
Eur J Immunol. 2009 Jan;39(1):50-5
pubmed: 19089816
Curr Drug Targets. 2009 Feb;10(2):104-9
pubmed: 19199905
Adv Exp Med Biol. 2009;647:174-85
pubmed: 19760074
Br J Haematol. 2010 Sep;150(5):565-73
pubmed: 20629661
Pathologica. 2010 Jun;102(3):83-7
pubmed: 21171509
Blood. 1990 Jan 1;75(1):174-9
pubmed: 2136802
Blood. 2011 Jul 28;118(4):874-83
pubmed: 21474675
J Biol Chem. 2011 Sep 2;286(35):30324-36
pubmed: 21757751
N Engl J Med. 2011 Nov 3;365(18):1673-83
pubmed: 22047558
ISRN Hematol. 2011;2011:623924
pubmed: 22084700
Am J Clin Pathol. 2011 Dec;136(6):944-53
pubmed: 22095381
Cytotherapy. 2012 Aug;14(7):830-40
pubmed: 22458956
Blood. 2012 Jun 14;119(24):5697-705
pubmed: 22535661
Cancer Cell. 2012 May 15;21(5):694-708
pubmed: 22624718
Drugs. 2012 Jun 18;72(9):1293-8
pubmed: 22686619
Br J Haematol. 2012 Nov;159(4):454-61
pubmed: 22994934
Eur J Immunol. 2013 May;43(5):1208-19
pubmed: 23420539
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
J Clin Oncol. 2013 Jun 1;31(16):1970-6
pubmed: 23610113
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
Blood. 2014 May 8;123(19):3007-15
pubmed: 24497534
J Clin Oncol. 2014 Apr 10;32(11):1157-63
pubmed: 24616310
J Dermatol. 2014 Mar;41(3):239-44
pubmed: 24628073
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
Blood. 2014 May 15;123(20):3095-100
pubmed: 24652992
Sci Transl Med. 2014 Jun 25;6(242):242ra83
pubmed: 24964991
Br J Haematol. 2015 Jan;168(1):38-45
pubmed: 25146490
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Mol Cancer Ther. 2015 Jul;14(7):1650-60
pubmed: 25934707
Histochem Cell Biol. 2015 Aug;144(2):133-46
pubmed: 25952155
Blood. 2015 Aug 20;126(8):983-92
pubmed: 26056165
Leukemia. 2016 Mar;30(3):701-7
pubmed: 26526988
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
J Clin Invest. 2016 Jul 1;126(7):2588-96
pubmed: 27270177
Oncotarget. 2016 Aug 30;7(35):56219-56232
pubmed: 27494836
Clin Cancer Res. 2017 Mar 1;23(5):1156-1166
pubmed: 27582488
Leukemia. 2017 Oct;31(10):2151-2160
pubmed: 28074066
Sci Transl Med. 2017 Jan 25;9(374):
pubmed: 28123068
Blood. 2017 Jul 20;130(3):285-296
pubmed: 28539325
Am J Hematol. 2017 Sep;92(9):892-901
pubmed: 28543380
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
J Clin Invest. 2017 Sep 1;127(9):3462-3471
pubmed: 28805662
Front Immunol. 2017 Oct 11;8:1272
pubmed: 29075259
Cancer Immunol Res. 2018 Jan;6(1):47-58
pubmed: 29079655
Nat Med. 2017 Dec;23(12):1416-1423
pubmed: 29131157
Blood Adv. 2017 Nov 21;1(25):2348-2360
pubmed: 29296885
Oncotarget. 2017 Nov 22;8(68):112783-112796
pubmed: 29348865
Leukemia. 2018 Sep;32(9):1970-1983
pubmed: 29483708
Front Immunol. 2018 Feb 15;9:283
pubmed: 29497427
Blood Adv. 2018 Mar 13;2(5):517-528
pubmed: 29507075
Blood. 2018 Jul 19;132(3):245-253
pubmed: 29699989
N Engl J Med. 2018 May 17;378(20):1947-1948
pubmed: 29768155
JCI Insight. 2018 Jul 12;3(13):
pubmed: 29997304
Cell Stem Cell. 2018 Aug 2;23(2):181-192.e5
pubmed: 30082067
Blood. 2018 Oct 4;132(14):1495-1506
pubmed: 30089630
J Clin Oncol. 2018 Oct 10;36(29):2926-2934
pubmed: 30138085
Nat Med. 2018 Oct;24(10):1499-1503
pubmed: 30275568
Curr Hematol Malig Rep. 2018 Dec;13(6):494-506
pubmed: 30317410
Nature. 1986 Sep 25-Oct 1;323(6086):346-9
pubmed: 3093892
Proc Natl Acad Sci U S A. 1979 Nov;76(11):5829-33
pubmed: 316538
Blood. 1986 Sep;68(3):752-61
pubmed: 3488778
Proc Natl Acad Sci U S A. 1985 Aug;82(15):5068-72
pubmed: 3860845
Nature. 1984 Dec 6-12;312(5994):541-5
pubmed: 6334238
J Immunol. 1984 Jul;133(1):137-46
pubmed: 6609971
J Immunol. 1994 Jan 15;152(2):517-26
pubmed: 7506726
Blood. 1995 Jan 1;85(1):1-14
pubmed: 7803786
Blood. 1993 Jul 15;82(2):343-62
pubmed: 8329694
Blood. 1996 Feb 1;87(3):893-9
pubmed: 8562959
Leuk Lymphoma. 1997 Jul;26(3-4):287-98
pubmed: 9322891
Leukemia. 1998 Jan;12(1):44-51
pubmed: 9436919
Int Immunol. 1997 Dec;9(12):1875-83
pubmed: 9466315
J Immunol. 1998 Jun 15;160(12):5749-56
pubmed: 9637484
J Immunol. 1998 Nov 15;161(10):5111-5
pubmed: 9820476